Herb-drug interactions and mechanistic and clinical considerations

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 640-651

  Chen, Xiao Wu ^a   Sneed, Kevin B ^b   Pan, Si Yuan ^c   Cao, Chuanhai ^b,d   Kanwar, Jagat R ^e   Chew, Helen ^b   Zhou, Shu Feng ^b  

^a SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e DEAKIN UNIVERSITY   (Australia)

Author keywords

CYP; Drug interaction; Herb medicine; P gp; Pharmacokinetics; Toxicity

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATORVASTATIN; CAFFEINE; CHLORZOXAZONE; CYCLOSPORIN; DEBRISOQUINE; DEXTROMETHORPHAN; DIGOXIN; DOCETAXEL; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; INDINAVIR; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; PHENPROCOUMON; PRAVASTATIN; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

AESCULUS HIPPOCASTANUM; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD PRESSURE; BREAST CANCER; COMA; DELIRIUM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECHINACEA PURPUREA; ENZYME INDUCTION; ENZYME INHIBITION; GARLIC; GENOTOXICITY; GINGER; GINKGO BILOBA; GINSENG; HERBAL MEDICINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; HYPERTENSION; IN VITRO STUDY; MANIA; MENSTRUATION; NONHUMAN; PHARMACOGENETICS; SABAL; SALVIA MILTIORRHIZA; SIDE EFFECT; SILYBUM MARIANUM; TANACETUM PARTHENIUM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84861878245     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050640     Document Type: Article

References (170)

1. Ernst, E. Herbal medicines: balancing benefits and risks. Novartis Found. Symp., 2007, 282(154-167; discussion 167-172, 212-158.
2. Sahoo, N.; Manchikanti, P.; Dey, S. Herbal drugs: standards and regulation. Fitoterapia, 2010, 81(6), 462-471.
3. Cravotto, G.; Boffa, L.; Genzini, L.; Garella, D. Phytotherapeutics: an evaluation of the potential of 1000 plants. J. Clin. Pharm. Ther., 2010, 35(1), 11-48.
4. Mehta, D. H.; Gardiner, P. M.; Phillips, R. S.; McCarthy, E. P. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J. Altern. Complement. Med., 2008, 14(10), 1263-1269.
5. Gunther, S.; Patterson, R. E.; Kristal, A. R.; Stratton, K. L.; White, E. Demographic and health-related correlates of herbal and specialty supplement use. J. Am. Diet Assoc., 2004, 104(1), 27-34.
6. Kennedy, J. Herb and supplement use in the US adult population. Clin. Ther., 2005, 27(11), 1847-1858.
7. Ulbricht, C.; Chao, W.; Costa, D.; Rusie-Seamon, E.; Weissner, W.; Woods, J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr. Drug Metab., 2008, 9(10), 1063-1120.
8. Shord, S. S.; Shah, K.; Lukose, A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr. Cancer Ther., 2009, 8(3), 208-227.
9. Di, Y. M.; Li, C. G.; Xue, C. C.; Zhou, S. F. Clinical drugs that interact with St. John's wort and implication in drug development. Curr. Pharm. Des., 2008, 14(17), 1723-1742.
10. Zhou, S. F.; Zhou, Z. W.; Li, C. G.; Chen, X.; Yu, X.; Xue, C. C.; Herington, A. Identification of drugs that interact with herbs in drug development. Drug Discov. Today, 2007, 12(15-16), 664-673.
11. Yang, A. K.; He, S. M.; Liu, L.; Liu, J. P.; Wei, M. Q.; Zhou, S. F. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr. Med. Chem., 2010, 17(16), 1635-1678.
12. Yang, X. X.; Hu, Z. P.; Duan, W.; Zhu, Y. Z.; Zhou, S. F. Drugherb interactions: eliminating toxicity with hard drug design. Curr. Pharm. Des., 2006, 12(35), 4649-4664.
13. Izzo, A. A. Herb-drug interactions: an overview of the clinical evidence. Fundam. Clin. Pharmacol., 2005, 19(1), 1-16.
14. Hu, Z.; Yang, X.; Ho, P. C.; Chan, S. Y.; Heng, P. W.; Chan, E.; Duan, W.; Koh, H. L.; Zhou, S. Herb-drug interactions: a literature review. Drugs, 2005, 65(9), 1239-1282.
15. Williamson, E. M. Interactions between herbal and conventional medicines. Expert Opin Drug Saf., 2005, 4(2), 355-378.
16. Izzo, A. A.; Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 2009, 69(13), 1777-1798.
17. Singh, Y. N. Potential for interaction of kava and St. John's wort with drugs. J. Ethnopharmacol., 2005, 100(1-2), 108-113.
18. Zhou, S. F.; Lai, X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr. Drug Metab., 2008, 9(5), 394-409.
19. Elmer, G. W.; Lafferty, W. E.; Tyree, P. T.; Lind, B. K. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann. Pharmacother., 2007, 41(10), 1617-1624.
20. Kennedy, D. A.; Seely, D. Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin. Drug Saf., 2010, 9(1), 79-124.
21. Mills, E.; Wu, P.; Johnston, B. C.; Gallicano, K.; Clarke, M.; Guyatt, G. Natural health product-drug interactions: a systematic review of clinical trials. Ther. Drug Monit., 2005, 27(5), 549-557.
22. Brulotte, J.; Vohra, S. Epidemiology of NHP-drug interactions: identification and evaluation. Curr. Drug Metab., 2008, 9(10), 1049-1054.
23. Colalto, C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacol. Res., 2010, 62(3), 207-227.
24. Jacob, A.; Pratuangdejkul, J.; Buffet, S.; Launay, J. M.; Manivet, P. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part II: The body in a Hilbertian space. Drug Discov. Today, 2009, 14(7-8), 406-412.
25. Huynh, L.; Masereeuw, R.; Friedberg, T.; Ingelman-Sundberg, M.; Manivet, P. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: Beyond the reduction of animal model use. Drug Discov. Today, 2009, 14(7-8), 401-405.
26. Khakar, P. S. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. Curr. Top. Med. Chem., 2010, 10(1), 116-126.
27. Hutter, M. C. In silico prediction of drug properties. Curr. Med. Chem., 2009, 16(2), 189-202.
28. Asha, S.; Vidyavathi, M. Role of human liver microsomes in in vitro metabolism of drugs - a review. Appl. Biochem. Biotechnol., 2010, 160(6), 1699-1722.
29. Lake, B. G.; Price, R. J.; Giddings, A. M.; Walters, D. G. In vitro assays for induction of drug metabolism. Methods Mol. Biol., 2009, 481, 47-58.
30. van de Kerkhof, E. G.; de Graaf, I. A.; Ungell, A. L.; Groothuis, G. M. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab. Dispos., 2008, 36(3), 604-613.
31. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek- Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9(3), 215-236.
32. Maguire, T. J.; Novik, E.; Chao, P.; Barminko, J.; Nahmias, Y.; Yarmush, M. L.; Cheng, K. C. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Curr. Drug Metab., 2009, 10(10), 1192-1199.
33. Gebhardt, R.; Hengstler, J. G.; Muller, D.; Glockner, R.; Buenning, P.; Laube, B.; Schmelzer, E.; Ullrich, M.; Utesch, D.; Hewitt, N.; Ringel, M.; Hilz, B. R.; Bader, A.; Langsch, A.; Koose, T.; Burger, H. J.; Maas, J.; Oesch, F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev., 2003, 35(2-3), 145-213.
34. Foti, R. S.; Wienkers, L. C.; Wahlstrom, J. L. Application of cytochrome P450 drug interaction screening in drug discovery. Comb. Chem. High Throughput Screen., 2010, 13(2), 145-158.
35. Giacomotto, J.; Segalat, L. High-throughput screening and small animal models, where are we? Br. J. Pharmacol., 2010, 160(2), 204-216.
36. Yale, S. H.; Glurich, I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J. Altern. Complement. Med., 2005, 11(3), 433-439.
37. Arrell, D. K.; Terzic, A. Network systems biology for drug discovery. Clin. Pharmacol. Ther., 2010, 88(1), 120-125.
38. Lai, Y.; Sampson, K. E.; Stevens, J. C. Evaluation of drug transporter interactions in drug discovery and development. Comb. Chem. High Throughput Screen., 2010, 13(2), 112-134.
39. Amore, B. M.; Gibbs, J. P.; Emery, M. G. Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. Comb. Chem. High Throughput Screen., 2010, 13(2), 207-218.
40. Marathe, P. H.; Rodrigues, A. D. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Curr. Drug Metab., 2006, 7(7), 687-704.
41. Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, R. S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 2003, 31(7), 815-832.
42. Yin, O. Q.; Tomlinson, B.; Waye, M. M.; Chow, A. H.; Chow, M. S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics, 2004, 14(12), 841-850.
43. Turpault, S.; Brian, W.; Van Horn, R.; Santoni, A.; Poitiers, F.; Donazzolo, Y.; Boulenc, X. Pharmacokinetic assessment of a fiveprobe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol., 2009, 68(6), 928-935.
44. Sevior, D. K.; Hokkanen, J.; Tolonen, A.; Abass, K.; Tursas, L.; Pelkonen, O.; Ahokas, J. T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica, 2010, 40(4), 245-254.
45. Chainuvati, S.; Nafziger, A. N.; Leeder, J. S.; Gaedigk, A.; Kearns, G. L.; Sellers, E.; Zhang, Y.; Kashuba, A. D.; Rowland, E.; Bertino, J. S., Jr. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther., 2003, 74(5), 437-447.
46. Zhu, B.; Ou-Yang, D. S.; Chen, X. P.; Huang, S. L.; Tan, Z. R.; He, N.; Zhou, H. H. Assessment of cytochrome P450 activity by a fivedrug cocktail approach. Clin. Pharmacol. Ther., 2001, 70(5), 455-461.
47. Wang, Z. Q.; Gorski, C.; Hamman, M. A.; Huang, S. M.; Lesko, L. J.; Hall, S. D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther., 2001, 70(4), 317-326.
48. Videau, O.; Delaforge, M.; Levi, M.; Thevenot, E.; Gal, O.; Becquemont, L.; Beaune, P.; Benech, H. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun. Mass Spectrom., 2010, 24(16), 2407-2419.
49. Iciek, M.; Kwiecien, I.; Wlodek, L. Biological properties of garlic and garlic-derived organosulfur compounds. Environ. Mol. Mutagen, 2009, 50(3), 247-265.
50. Markowitz, J. S.; Devane, C. L.; Chavin, K. D.; Taylor, R. M.; Ruan, Y.; Donovan, J. L. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin. Pharmacol. Ther., 2003, 74(2), 170-177.
51. Gurley, B. J.; Gardner, S. F.; Hubbard, M. A.; Williams, D. K.; Gentry, W. B.; Cui, Y.; Ang, C. Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther., 2002, 72(3), 276-287.
52. Gurley, B. J.; Gardner, S. F.; Hubbard, M. A.; Williams, D. K.; Gentry, W. B.; Cui, Y.; Ang, C. Y. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging, 2005, 22(6), 525-539.
53. Cox, M. C.; Low, J.; Lee, J.; Walshe, J.; Denduluri, N.; Berman, A.; Permenter, M. G.; Petros, W. P.; Price, D. K.; Figg, W. D.; Sparreboom, A.; Swain, S. M. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin. Cancer Res., 2006, 12(15), 4636-4640.
54. Gwilt, P. R.; Lear, C. L.; Tempero, M. A.; Birt, D. D.; Grandjean, A. C.; Ruddon, R. W.; Nagel, D. L. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol. Biomarkers Prev., 1994, 3(2), 155-160.
55. Piscitelli, S. C.; Burstein, A. H.; Welden, N.; Gallicano, K. D.; Falloon, J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis., 2002, 34(2), 234-238.
56. Hajda, J.; Rentsch, K. M.; Gubler, C.; Steinert, H.; Stieger, B.; Fattinger, K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur. J. Pharm. Sci., 2010, 41(5), 729-735.
57. Laroche, M.; Choudhri, S.; Gallicano, K.; Foster, B. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can. J. Infect. Dis., 1998, 9(Suppl A), 471P.
58. Fitzsimmons, M. E.; Collins, J. M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos., 1997, 25(2), 256-266.
59. Kim, A. E.; Dintaman, J. M.; Waddell, D. S. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther., 1998, 286, 143-149.
60. Markowitz, J. S.; Devane, C. L.; Chavin, K. D.; Taylor, R. M.; Ruan, Y.; Donovan, J. L. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin. Pharmacol. Ther., 2003, 74(2), 170-177.
61. Sunter, W. H. Warfarin and garlic. Pharm. J., 1991, 246, 772.
62. Evans, V. Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use. J. Neurosci. Nurs., 2000, 32(4), 229-232.
63. Mohammed Abdul, M. I.; Jiang, X.; Williams, K. M.; Day, R. O.; Roufogalis, B. D.; Liauw, W. S.; Xu, H.; McLachlan, A. J. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br. J. Pharmacol., 2008, 154(8), 1691-1700.
64. Rahman, K.; Billington, D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J. Nutr., 2000, 130(11), 2662-2665.
65. Hiyasat, B.; Sabha, D.; Grotzinger, K.; Kempfert, J.; Rauwald, J. W.; Mohr, F. W.; Dhein, S. Antiplatelet activity of Allium ursinum and Allium sativum. Pharmacology, 2009, 83(4), 197-204.
66. Wojcikowski, K.; Myers, S.; Brooks, L. Effects of garlic oil on platelet aggregation: a double-blind placebo-controlled crossover study. Platelets, 2007, 18(1), 29-34.
67. Weinmann, S.; Roll, S.; Schwarzbach, C.; Vauth, C.; Willich, S. N. Effects of Ginkgo biloba in dementia: systematic review and metaanalysis. BMC Geriatr., 2010, 10, 14.
68. Birks, J.; Grimley Evans, J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev., 2009, 1, CD003120.
69. van Beek, T. A. Chemical analysis of Ginkgo biloba leaves and extracts. J. Chromatogr. A, 2002, 967(1), 21-55.
70. Engelsen, J.; Nielsen, J. D.; Hansen, K. F. [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebocontrolled cross-over trial]. Ugeskr Laeger, 2003, 165(18), 1868-1871.
71. Jiang, X.; Williams, K. M.; Liauw, W. S.; Ammit, A. J.; Roufogalis, B. D.; Duke, C. C.; Day, R. O.; McLachlan, A. J. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 2005, 59(4), 425-432.
72. Zuo, X. C.; Zhang, B. K.; Jia, S. J.; Liu, S. K.; Zhou, L. Y.; Li, J.; Zhang, J.; Dai, L. L.; Chen, B. M.; Yang, G. P.; Yuan, H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur. J. Clin. Pharmacol., 2010, 66(5), 503-509.
73. Lei, H. P.; Wang, G.; Wang, L. S.; Ou-yang, D. S.; Chen, H.; Li, Q.; Zhang, W.; Tan, Z. R.; Fan, L.; He, Y. J.; Zhou, H. H. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann. Pharmacother., 2009, 43(4), 726-731.
74. Markowitz, J. S.; Donovan, J. L.; Lindsay DeVane, C.; Sipkes, L.; Chavin, K. D. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol., 2003, 23(6), 576-581.
75. Lei, H. P.; Ji, W.; Lin, J.; Chen, H.; Tan, Z. R.; Hu, D. L.; Liu, L. J.; Zhou, H. H. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br. J. Clin. Pharmacol., 2009, 68(2), 201-206.
76. Uchida, S.; Yamada, H.; Li, X. D.; Maruyama, S.; Ohmori, Y.; Oki, T.; Watanabe, H.; Umegaki, K.; Ohashi, K.; Yamada, S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., 2006, 46(11), 1290-1298.
77. Greenblatt, D. J.; von Moltke, L. L.; Luo, Y.; Perloff, E. S.; Horan, K. A.; Bruce, A.; Reynolds, R. C.; Harmatz, J. S.; Avula, B.; Khan, I. A.; Goldman, P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J. Clin. Pharmacol., 2006, 46(2), 214-221.
78. Mohutsky, M. A.; Anderson, G. D.; Miller, J. W.; Elmer, G. W. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am. J. Ther., 2006, 13(1), 24-31.
79. Robertson, S. M.; Davey, R. T.; Voell, J.; Formentini, E.; Alfaro, R. M.; Penzak, S. R. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin., 2008, 24(2), 591-599.
80. Fan, L.; Tao, G. Y.; Wang, G.; Chen, Y.; Zhang, W.; He, Y. J.; Li, Q.; Lei, H. P.; Jiang, F.; Hu, D. L.; Huang, Y. F.; Zhou, H. H. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother., 2009, 43(5), 944-949.
81. Kudolo, G. B.; Wang, W.; Javors, M.; Blodgett, J. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects - a double blind placebo-controlled, crossover study. Clin. Nutr., 2006, 25(4), 606-616.
82. Leung, K. W.; Wong, A. S. Pharmacology of ginsenosides: a literature review. Chin. Med., 2010, 5, 20.
83. Christensen, L. P. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res., 2009, 55, 1-99.
84. Lee, F. C.; Ko, J. H.; Park, J. K.; Lee, J. S. Effects of Panax ginseng on blood alcohol clearance in man. Clin. Exp. Pharmacol. Physiol., 1987, 14(6), 543-546.
85. Jiang, X.; Blair, E. Y.; McLachlan, A. J. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J. Clin. Pharmacol., 2006, 46(11), 1370-1378.
86. Wallace, S.; Carrier, D.; Clausen, E. Extraction of nutraceuticals from milk thistle: Part II. Extraction with organic solvents. Appl. Biochem. Biotechnol., 2003, 108(1-3), 891-904.
87. Kvasnicka, F.; Biba, B.; Sevcik, R.; Voldrich, M.; Kratka, J. Analysis of the active components of silymarin. J. Chromatogr. A, 2003, 990(1-2), 239-245.
88. Sridar, C.; Goosen, T. C.; Kent, U. M.; Williams, J. A.; Hollenberg, P. F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32(6), 587-594.
89. Han, Y.; Guo, D.; Chen, Y.; Chen, Y.; Tan, Z. R.; Zhou, H. H. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur. J. Clin. Pharmacol., 2009, 65(6), 585-591.
90. Rajnarayana, K.; Reddy, M. S.; Vidyasagar, J.; Krishna, D. R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung, 2004, 54(2), 109-113.
91. Fuhr, U.; Beckmann-Knopp, S.; Jetter, A.; Luck, H.; Mengs, U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med., 2007, 73(14), 1429-1435.
92. van Erp, N. P.; Baker, S. D.; Zhao, M.; Rudek, M. A.; Guchelaar, H. J.; Nortier, J. W.; Sparreboom, A.; Gelderblom, H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res., 2005, 11(21), 7800-7806.
93. Mills, E.; Wilson, K.; Clarke, M.; Foster, B.; Walker, S.; Rachlis, B.; DeGroot, N.; Montori, V. M.; Gold, W.; Phillips, E.; Myers, S.; Gallicano, K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur. J. Clin. Pharmacol., 2005, 61(1), 1-7.
94. Deng, J. W.; Shon, J. H.; Shin, H. J.; Park, S. J.; Yeo, C. W.; Zhou, H. H.; Song, I. S.; Shin, J. G. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm. Res., 2008, 25(8), 1807-1814.
95. Gurley, B. J.; Swain, A.; Hubbard, M. A.; Williams, D. K.; Barone, G.; Hartsfield, F.; Tong, Y.; Carrier, D. J.; Cheboyina, S.; Battu, S. K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol. Nutr. Food Res., 2008, 52(7), 755-763.
96. Rao, B. N.; Srinivas, M.; Kumar, Y. S.; Rao, Y. M. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol. Drug Interact., 2007, 22(2-3), 175-185.
97. Gurley, B.; Hubbard, M. A.; Williams, D. K.; Thaden, J.; Tong, Y.; Gentry, W. B.; Breen, P.; Carrier, D. J.; Cheboyina, S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol., 2006, 46(2), 201-213.
98. Gurley, B. J.; Gardner, S. F.; Hubbard, M. A.; Williams, D. K.; Gentry, W. B.; Carrier, J.; Khan, I. A.; Edwards, D. J.; Shah, A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther., 2004, 76(5), 428-440.
99. Linde, K. St. John's wort - an overview. Forsch Komplementmed., 2009, 16(3), 146-155.
100. Sarris, J.; Kavanagh, D. J. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J. Altern. Complement. Med., 2009, 15(8), 827-836.
101. Crockett, S. L. Essential oil and volatile components of the genus Hypericum (Hypericaceae). Nat. Prod. Commun., 2010, 5(9), 1493-1506.
102. Hafner, V.; Jager, M.; Matthee, A. K.; Ding, R.; Burhenne, J.; Haefeli, W. E.; Mikus, G. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin. Pharmacol. Ther., 2010, 87(2), 191-196.
103. Xu, H.; Williams, K. M.; Liauw, W. S.; Murray, M.; Day, R. O.; McLachlan, A. J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br. J. Pharmacol., 2008, 153(7), 1579-1586.
104. Schwarz, U. I.; Hanso, H.; Oertel, R.; Miehlke, S.; Kuhlisch, E.; Glaeser, H.; Hitzl, M.; Dresser, G. K.; Kim, R. B.; Kirch, W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther., 2007, 81(5), 669-678.
105. Lundahl, A.; Hedeland, M.; Bondesson, U.; Knutson, L.; Lennernas, H. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur. J. Pharm. Sci., 2009, 36(4-5), 433-443.
106. Nieminen, T. H.; Hagelberg, N. M.; Saari, T. I.; Neuvonen, M.; Laine, K.; Neuvonen, P. J.; Olkkola, K. T. St John's wort greatly reduces the concentrations of oral oxycodone. Eur. J. Pain, 2010, 14(8), 854-859.
107. Lei, H. P.; Yu, X. Y.; Xie, H. T.; Li, H. H.; Fan, L.; Dai, L. L.; Chen, Y.; Zhou, H. H. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. Xenobiotica, 2010, 40(4), 275-281.
108. Wang, X. D.; Li, J. L.; Su, Q. B.; Guan, S.; Chen, J.; Du, J.; He, Y. W.; Zeng, J.; Zhang, J. X.; Chen, X.; Huang, M.; Zhou, S. F. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. Br. J. Clin. Pharmacol., 2009, 67(2), 255-261.
109. Andren, L.; Andreasson, A.; Eggertsen, R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur. J. Clin. Pharmacol., 2007, 63(10), 913-916.
110. Kawaguchi, A.; Ohmori, M.; Tsuruoka, S.; Nishiki, K.; Harada, K.; Miyamori, I.; Yano, R.; Nakamura, T.; Masada, M.; Fujimura, A. Drug interaction between St John's Wort and quazepam. Br. J. Clin. Pharmacol., 2004, 58(4), 403-410.
111. Bauer, S.; Stormer, E.; Johne, A.; Kruger, H.; Budde, K.; Neumayer, H. H.; Roots, I.; Mai, I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br. J. Clin. Pharmacol., 2003, 55(2), 203-211.
112. Smith, P.; Bullock, J. M.; Booker, B. M.; Haas, C. E.; Berenson, C. S.; Jusko, W. J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy, 2004, 24(11), 1508-1514.
113. Mathijssen, R. H.; Verweij, J.; de Bruijn, P.; Loos, W. J.; Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst., 2002, 94(16), 1247-1249.
114. Frye, R. F.; Fitzgerald, S. M.; Lagattuta, T. F.; Hruska, M. W.; Egorin, M. J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther., 2004, 76(4), 323-329.
115. Eich-Hochli, D.; Oppliger, R.; Golay, K. P.; Baumann, P.; Eap, C. B. Methadone maintenance treatment and St. John's wort - A case report. Pharmacopsychiatry, 2003, 36(1), 35-37.
116. Piscitelli, S. C.; Burstein, A. H.; Chaitt, D.; Alfaro, R. M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet, 2000, 355(9203), 547-548.
117. de Maat, M. M.; Hoetelmans, R. M.; Mathot, R. A.; van Gorp, E. C.; Meenhorst, P. L.; Mulder, J. W.; Beijnen, J. H. Drug interaction between St John's wort and nevirapine. AIDS, 2001, 15(3), 420-421.
118. Mai, I.; Stormer, E.; Bauer, S.; Kruger, H.; Budde, K.; Roots, I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol. Dial. Transplant, 2003, 18(4), 819-822.
119. Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit- Singh, C. J.; Willson, T. M. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7500-7502.
120. Roby, C. A.; Anderson, G. D.; Kantor, E.; Dryer, D. A.; Burstein, A. H. St John's Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther., 2000, 67(5), 451-457.
121. Liu, Y. H.; Mo, S. L.; Bi, H. C.; Hu, B. F.; Li, C. G.; Wang, Y. T.; Huang, L.; Huang, M.; Duan, W.; Liu, J. P.; Wei, M. Q.; Zhou, S. F. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica, 2011, 41(4), 259-280.
122. Verma, S.; Tabb, M. M.; Blumberg, B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer, 2009, 9, 3.
123. Bano, G.; Raina, R. K.; Zutshi, U.; Bedi, K. L.; Johri, R. K.; Sharma, S. C. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur. J. Clin. Pharmacol., 1991, 41(6), 615-617.
124. Fan, L.; Zhang, W.; Guo, D.; Tan, Z. R.; Xu, P.; Li, Q.; Liu, Y. Z.; Zhang, L.; He, T. Y.; Hu, D. L.; Wang, D.; Zhou, H. H. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin. Pharmacol. Ther., 2008, 83(3), 471-476.
125. Castellone, D. D.; Van Cott, E. M. Laboratory monitoring of new anticoagulants. Am. J. Hematol., 2010, 85(3), 185-187.
126. Bovill, E. G.; Fung, M.; Cushman, M. Vitamin K and oral anticoagulation: thought for food. Am. J. Med., 2004, 116(10), 711-713.
127. Stehle, S.; Kirchheiner, J.; Lazar, A.; Fuhr, U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinet., 2008, 47(9), 565-594.
128. Kuruvilla, M.; Gurk-Turner, C. A review of warfarin dosing and monitoring. Proc. (Bayl Univ. Med. Cent.), 2001, 14(3), 305-306.
129. Kaminsky, L. S.; Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
130. Greenblatt, D. J.; von Moltke, L. L. Interaction of warfarin with drugs, natural substances, and foods. J. Clin. Pharmacol., 2005, 45(2), 127-132.
131. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 2008, 9(4), 310-322.
132. Zhou, S. F.; Zhou, Z. W.; Yang, L. P.; Cai, J. P. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem., 2009, 16(27), 3480-3675.
133. Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton, J. W. Interactions of herbs with cytochrome P450. Drug Metab. Rev., 2003, 35(1), 35-98.
134. Zhou, S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 2008, 38(7), 802-832.
135. Yeung, E. Y.; Sueyoshi, T.; Negishi, M.; Chang, T. K. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab. Dispos., 2008, 36(11), 2270-2276.
136. Lau, A. J.; Yang, G.; Rajaraman, G.; Baucom, C. C.; Chang, T. K. Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J. Pharmacol. Exp. Ther., 2010, 335(3), 771-780.
137. Brobst, D. E.; Ding, X.; Creech, K. L.; Goodwin, B.; Kelley, B.; Staudinger, J. L. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 310(2), 528-535.
138. Mu, Y.; Zhang, J.; Zhang, S.; Zhou, H. H.; Toma, D.; Ren, S.; Huang, L.; Yaramus, M.; Baum, A.; Venkataramanan, R.; Xie, W. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J. Pharmacol. Exp. Ther., 2006, 316(3), 1369-1377.
139. Yu, C.; Ye, S.; Sun, H.; Liu, Y.; Gao, L.; Shen, C.; Chen, S.; Zeng, S. PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem. Biol. Interact., 2009, 177(1), 58-64.
140. Lichti-Kaiser, K.; Staudinger, J. L. The traditional Chinese herbal remedy tian xian activates pregnane X receptor and induces CYP3A gene expression in hepatocytes. Drug Metab. Dispos., 2008, 36(8), 1538-1545.
141. Zhou, S.; Lim, L. Y.; Chowbay, B. Herbal modulation of Pglycoprotein. Drug Metab. Rev., 2004, 36(1), 57-104.
142. Durr, D.; Stieger, B.; Kullak-Ublick, G. A.; Rentsch, K. M.; Steinert, H. C.; Meier, P. J.; Fattinger, K. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 2000, 68(6), 598-604.
143. Hennessy, M.; Kelleher, D.; Spiers, J. P.; Barry, M.; Kavanagh, P.; Back, D.; Mulcahym, F.; Feely, J. St John's wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol., 2002, 53(1), 75-82.
144. Dresser, G. K.; Schwarz, U. I.; Wilkinson, G. R.; Kim, R. B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther., 2003, 73(1), 41-50.
145. von Richter, O.; Burk, O.; Fromm, M. F.; Thon, K. P.; Eichelbaum, M.; Kivisto, K. T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther., 2004, 75(3), 172-183.
146. Berggren, S.; Gall, C.; Wollnitz, N.; Ekelund, M.; Karlbom, U.; Hoogstraate, J.; Schrenk, D.; Lennernas, H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm., 2007, 4(2), 252-257.
147. Kato, M.; Chiba, K.; Hisaka, A.; Ishigami, M.; Kayama, M.; Mizuno, N.; Nagata, Y.; Takakuwa, S.; Tsukamoto, Y.; Ueda, K.; Kusuhara, H.; Ito, K.; Sugiyama, Y. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoproteinquantitative analysis based on information from the literature. Drug Metab. Pharmacokinet., 2003, 18(6), 365-372.
148. Fugh-Berman, A. Herb-drug interactions. Lancet, 2000, 355(9198), 134-138.
149. Ruschitzka, F.; Meier, P. J.; Turina, M.; Luscher, T. F.; Noll, G. Acute heart transplant rejection due to Saint John's wort. Lancet, 2000, 355(9203), 548-549.
150. Moschella, C.; Jaber, B. L. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am. J. Kidney Dis., 2001, 38(5), 1105-1107.
151. Wittkowsky, A. K. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J. Thromb. Thrombolysis, 2008, 25(1), 72-77.
152. Lantz, M. S.; Buchalter, E.; Giambanco, V. St. John's wort and antidepressant drug interactions in the elderly. J. Geriatr. Psychiatr. Neurol., 1999, 12(1), 7-10.
153. Gordon, J. B. SSRIs and St.John's Wort: possible toxicity? Am. Fam. Physician, 1998, 57(5), 950.
154. Barbenel, D. M.; Yusufi, B.; O'Shea, D.; Bench, C. J. Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. J. Psychopharmacol., 2000, 14(1), 84-86.
155. Spinella, M.; Eaton, L. A. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj., 2002, 16(4), 359-367.
156. Dannawi, M. Possible serotonin syndrome after combination of buspirone and St John's Wort. J. Psychopharmacol., 2002, 16(4), 401.
157. Cookson, J. Side-effects of antidepressants. Br. J. Psychiatry, 1993, 163(Suppl 20), 20-24.
158. Shader, R. I.; Greenblatt, D. J. Phenelzine and the dream machine - ramblings and reflections. J. Clin. Psychopharmacol., 1985, 5(2), 65.
159. Jones, B. D.; Runikis, A. M. Interaction of ginseng with phenelzine. J. Clin. Psychopharmacol., 1987, 7(3), 201-202.
160. Shaw, D.; Leon, C.; Kolev, S.; Murray, V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf., 1997, 17(5), 342-356.
161. Galluzzi, S.; Zanetti, O.; Binetti, G.; Trabucchi, M.; Frisoni, G. B. Coma in a patient with Alzheimer's disease taking low dose trazodone and Ginkgo biloba. J. Neurol. Neurosurg. Psychiatr., 2000, 68(5), 679-680.
162. Izzat, M. B.; Yim, A. P. C.; El-Zufari, M. H. A taste of Chinese medicine! Ann. Thorac. Surg., 1998, 66(3), 941-942.
163. Almeida, J. C.; Grimsley, E. W. Coma from the health food store: interaction between Kava and alprazolam. Ann. Intern. Med., 1996, 125(11), 940-941.
164. Schelosky, L.; Raffauf, C.; Jendroska, K.; Poewe, W. Kava and dopamine antagonism. J. Neurol. Neurosurg. Psychiatry, 1995, 58(5), 639-640.
165. Baum, S. S.; Hill, R.; Rommelspacher, H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol. Biol. Psychiatry, 1998, 22(7), 1105-1120.
166. Markowitz, J. S.; von Moltke, L. L.; Donovan, J. L. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol. Nutr. Food Res., 2008, 52(7), 747-754.
167. Perdaems, N.; Blasco, H.; Vinson, C.; Chenel, M.; Whalley, S.; Cazade, F.; Bouzom, F. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin. Pharmacokinet., 2010, 49(4), 239-258.
168. Fenner, K. S.; Troutman, M. D.; Kempshall, S.; Cook, J. A.; Ware, J. A.; Smith, D. A.; Lee, C. A. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther., 2009, 85(2), 173-181.
169. Zhou, S.; Huang, M.; Xu, A.; Yang, H.; Duan, W.; Paxton, J. W. Prediction of herb-drug metabolic interactions: a simulation study. Phytother. Res., 2005, 19(6), 464-471.
170. Ernst, E.; Pittler, M. H. Herbal medicine. Med. Clin. North Am., 2002, 86(1), 149-161.